BIT:DIA

Stock Analysis Report

Executive Summary

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital analysis laboratories worldwide.


Snowflake Analysis

Excellent balance sheet with proven track record.


Similar Companies

Share Price & News

How has DiaSorin's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DIA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-12.1%

DIA

-2.1%

IT Medical Equipment

-7.2%

IT Market


1 Year Return

23.4%

DIA

26.8%

IT Medical Equipment

8.2%

IT Market

Return vs Industry: DIA exceeded the Italian Medical Equipment industry which returned 26.8% over the past year.

Return vs Market: DIA exceeded the Italian Market which returned 8.2% over the past year.


Shareholder returns

DIAIndustryMarket
7 Day-12.1%-2.1%-7.2%
30 Day-7.6%-1.9%-3.3%
90 Day-11.3%4.2%-2.2%
1 Year24.5%23.4%28.7%26.8%12.9%8.2%
3 Year88.3%77.9%76.9%67.9%29.0%16.0%
5 Year221.1%195.3%116.7%96.0%8.8%-28.3%

Price Volatility Vs. Market

How volatile is DiaSorin's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DiaSorin undervalued compared to its fair value and its price relative to the market?

36.2x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DIA (€110.2) is trading above our estimate of fair value (€67.48)

Significantly Below Fair Value: DIA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DIA is good value based on its PE Ratio (37.5x) compared to the Medical Equipment industry average (38x).

PE vs Market: DIA is poor value based on its PE Ratio (37.5x) compared to the Italian market (17.7x).


Price to Earnings Growth Ratio

PEG Ratio: DIA is poor value based on its PEG Ratio (3.8x)


Price to Book Ratio

PB vs Industry: DIA is overvalued based on its PB Ratio (8.1x) compared to the XE Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is DiaSorin forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

9.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DIA's forecast earnings growth (9.8% per year) is above the savings rate (1.2%).

Earnings vs Market: DIA's earnings (9.8% per year) are forecast to grow slower than the Italian market (10% per year).

High Growth Earnings: DIA's earnings are forecast to grow, but not significantly.

Revenue vs Market: DIA's revenue (7.5% per year) is forecast to grow faster than the Italian market (4.2% per year).

High Growth Revenue: DIA's revenue (7.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DIA's Return on Equity is forecast to be low in 3 years time (18.1%).


Next Steps

Past Performance

How has DiaSorin performed over the past 5 years?

15.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DIA has high quality earnings.

Growing Profit Margin: DIA's current net profit margins (24%) are lower than last year (24.3%).


Past Earnings Growth Analysis

Earnings Trend: DIA's earnings have grown by 15% per year over the past 5 years.

Accelerating Growth: DIA's earnings growth over the past year (4.4%) is below its 5-year average (15% per year).

Earnings vs Industry: DIA earnings growth over the past year (4.4%) exceeded the Medical Equipment industry 2%.


Return on Equity

High ROE: DIA's Return on Equity (20.7%) is considered high.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is DiaSorin's financial position?


Financial Position Analysis

Short Term Liabilities: DIA's short term assets (€338.6M) exceed its short term liabilities (€154.9M).

Long Term Liabilities: DIA's short term assets (€338.6M) do not cover its long term liabilities (€-93.6M).


Debt to Equity History and Analysis

Debt Level: DIA is debt free.

Reducing Debt: DIA has no debt compared to 5 years ago when its debt to equity ratio was 0.7%.

Debt Coverage: DIA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: DIA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: DIA has a high level of physical assets or inventory.

Debt Coverage by Assets: DIA's debt is not covered by short term assets (assets are -11.4x debt).


Next Steps

Dividend

What is DiaSorin's current dividend yield, its reliability and sustainability?

0.85%

Current Dividend Yield


Dividend Yield vs Market

company0.8%marketbottom25%2.1%markettop25%4.7%industryaverage1.4%forecastin3Years1.2%

Current dividend yield vs market & industry

Notable Dividend: DIA's dividend (0.82%) isn’t notable compared to the bottom 25% of dividend payers in the Italian market (2.09%).

High Dividend: DIA's dividend (0.82%) is low compared to the top 25% of dividend payers in the Italian market (4.73%).


Stability and Growth of Payments

Stable Dividend: DIA is not paying a notable dividend for the Italian market, therefore no need to check if payments are stable.

Growing Dividend: DIA is not paying a notable dividend for the Italian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: DIA is not paying a notable dividend for the Italian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DIA's dividend in 3 years as they are not forecast to pay a notable one for the Italian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.9yrs

Average management tenure


CEO

Carlo Rosa (53yo)

14.1yrs

Tenure

€1,330,000

Compensation

Mr. Carlo Rosa has been the Chief Executive Officer of DiaSorin S.p.A. since 2006 and has been its General Manager since April 27, 2010 also its Executive Director since March 26, 2007. In 2001, Mr. Rosa l ...


CEO Compensation Analysis

Compensation vs Market: Carlo's total compensation ($USD0.00) is below average for companies of similar size in the Italian market ($USD2.69M).

Compensation vs Earnings: Carlo's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Carlo Rosa
CEO, GM & Executive Director14.1yrs€1.33m5.83% 338.5m
Chen Even
Chief Commercial Officer12.9yrs€663.00kno data
Piergiorgio Pedron
Corporate Accounting Documents Officer3.8yrsno datano data
Riccardo Fava
Senior Director of Investor Relations & Corporate Communication0yrsno datano data
Marco Minolfo
Manager of the Corporate Legal Affairs Department0yrsno datano data
Stefano Ronchi
Senior Corporate Vice President of Human Resources0yrsno datano data
John Gerace
President of DiaSorin Molecular LLC1.1yrsno datano data

3.9yrs

Average Tenure

54.5yo

Average Age

Experienced Management: DIA's management team is considered experienced (3.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Carlo Rosa
CEO, GM & Executive Director14.1yrs€1.33m5.83% 338.5m
Chen Even
Chief Commercial Officer12.9yrs€663.00kno data
Gustavo Denegri
Chairman9.8yrs€400.00kno data
Enrico Amo
Non-Executive Director12.9yrs€35.00kno data
Michele Denegri
Deputy Chairman6.8yrs€150.00kno data
Francesco Moscetti
Independent Director12.9yrs€55.00kno data
Giuseppe Alessandria
Lead Independent Director6.8yrs€45.00kno data
Stefano Altara
Non-Executive Director5.8yrs€35.00kno data
Roberta Somati
Independent Director6.8yrs€35.00kno data
Monica Mannino
Chairman of Board of Statutory Auditors3.8yrsno datano data

8.3yrs

Average Tenure

54.5yo

Average Age

Experienced Board: DIA's board of directors are considered experienced (8.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DIA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DiaSorin S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DiaSorin S.p.A.
  • Ticker: DIA
  • Exchange: BIT
  • Founded: 1968
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €5.810b
  • Shares outstanding: 54.66m
  • Website: https://www.diasoringroup.com

Number of Employees


Location

  • DiaSorin S.p.A.
  • Via Crescentino
  • Saluggia
  • Vercelli
  • 13040
  • Italy

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DIABIT (Borsa Italiana)YesCommon SharesITEURJul 2007
34DDB (Deutsche Boerse AG)YesCommon SharesDEEURJul 2007
DSRL.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJul 2007
0GZXLSE (London Stock Exchange)YesCommon SharesGBEURJul 2007
DIAMBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURJul 2007

Biography

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital analysis laboratories worldwide. The company offers tests for diagnosis in a range of clinical areas, such as infectious diseases, gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various technological platforms, including LIAISON XL and LIAISON XS analyzer systems; and LIAISON MDX instrument, a thermocycler. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. DiaSorin S.p.A. was founded in 1968 and is headquartered in Saluggia, Italy. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 21:26
End of Day Share Price2020/02/25 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.